Mandashi invests in Ethical Biotech Pioneer Sansanima

May 2025 – Sheffield, UK – Mandashi is proud to announce its investment in Sansanima, a University of Sheffield spinout revolutionising pharmaceutical safety testing.

Sansanima has developed a pioneering human cell-based testing platform that offers a compelling ethical and technical alternative to traditional animal testing in the production of life-saving medicines, including vaccines for tetanus and botulinum toxin-based therapies. The company’s breakthrough aligns with recent moves by global regulators, including the US FDA, to phase out mandatory animal testing – signalling a growing global demand for modern, humane solutions.

Dr. Andy Evans, Director of Mandashi, commented:

“We are thrilled to support Sansanima in their mission to modernise pharmaceutical safety testing. This investment reflects our commitment to backing outstanding local science with global relevance, setting the tone for a future focused on responsible innovation, regional growth, and national impact.”